TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36570150

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with probiotics (10 unspecified dosage)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mediterranean diet without probiotics (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Other unspecified dietary interventions
Number of subjects: 50
Study: 36570171

Group type: EXPERIMENTAL
Intervention: Enema containing ReFerm
Number of subjects: 30
Study: 36570498

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 times a week + Treatment as Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 0
Study: 36570649

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 36570810

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 66
Study: 36570815

Group type: EXPERIMENTAL
Intervention: Chelation therapy for divalent metals (lead and cadmium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Legislation, mitigation and control of pollutants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Environmental policies for heart-healthy spaces
Number of subjects: 0
Study: 36570829

Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 57

Group type: COMPARATOR
Intervention: Exteroceptive comparison condition (watching a relaxing nature film)
Number of subjects: 57
Study: 36571164

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) for patients with underlying ICAD
Number of subjects: 315

Group type: COMPARATOR
Intervention: Endovascular therapy (EVT) for patients without underlying ICAD
Number of subjects: 315
Study: 36571171

Group type: EXPERIMENTAL
Intervention: Combined chlorpheniramine 10 mg and ranitidine 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study: 36571569

Group type: EXPERIMENTAL
Intervention: ticagrelor/aspirin
Number of subjects: 5796

Group type: COMPARATOR
Intervention: clopidogrel/aspirin
Number of subjects: 5796
Study: 36571611

Group type: EXPERIMENTAL
Intervention: Topical cetirizine with minoxidil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topical minoxidil with placebo
Number of subjects: 66
Study: 36571701

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (QD) for induction
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD for maintenance
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Upadacitinib 15 mg QD for maintenance
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib (various doses 7.5-45 mg QD for induction and 15-30 mg QD for maintenance)
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 1683
Study: 36571770

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg intravenously every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg intravenously every 2 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 83
Study: 36571826

Group type: EXPERIMENTAL
Intervention: Cold therapy applied 10 minutes before port needle removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 36571973

Group type: EXPERIMENTAL
Intervention: STIGMA video
Number of subjects: 49

Group type: COMPARATOR
Intervention: NEUTRAL video
Number of subjects: 49
Study: 36572129

Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Conventional EMR (CEMR)
Number of subjects: 298
Study: 36572184

Group type: EXPERIMENTAL
Intervention: Dupilumab (P2B: pooled 200/300 mg; VENTURE: 300 mg) every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36572202

Group type: EXPERIMENTAL
Intervention: Arm rowing (AO)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) rowing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no structured exercise)
Number of subjects: 27
Study: 36572239

Group type: EXPERIMENTAL
Intervention: Peer Whole Health (18 sessions over 6 months)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC; primary care and data analytics)
Number of subjects: 220
Study: 36572280

Group type: EXPERIMENTAL
Intervention: Intensified neoadjuvant CRT followed by adjuvant CT
Number of subjects: 913

Group type: COMPARATOR
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 913
Study: 36572373

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36572500

Group type: EXPERIMENTAL
Intervention: Therapist-guided I-BA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-guided I-BA
Number of subjects: 32

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 32
Study: 36572501

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT scan
Number of subjects: 500
Study: 36572534

Group type: EXPERIMENTAL
Intervention: D-cycloserine during pulmonary rehabilitation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Brain imaging markers of breathlessness-expectation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Questionnaires and clinical measures
Number of subjects: 71
Study: 36572571

Group type: EXPERIMENTAL
Intervention: Capivasertib 400 mg (orally, twice daily, with an intermittent schedule of 4 days on, 3 days off) plus abiraterone acetate 1000 mg (orally administered once daily) and prednisone 5 mg (twice daily)
Number of subjects: 27
Study: 36572869

Group type: EXPERIMENTAL
Intervention: Changing clinics (15% of participants)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Not changing clinics (85% of participants)
Number of subjects: 675
Study: 36572870

Group type: COMPARATOR
Intervention: Standard care well-child visits (WCV)
Number of subjects: 2025

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measure (PRO WCV)
Number of subjects: 2025

Group type: EXPERIMENTAL
Intervention: PRO WCV plus Food Care (telehealth coaching and grocery store tour)
Number of subjects: 2025

Group type: EXPERIMENTAL
Intervention: All interventions (Standard WCV, PRO WCV, PRO WCV plus Food Care)
Number of subjects: 2025
Study: 36572884

Group type: EXPERIMENTAL
Intervention: 6-week specific rehabilitation program combining education and exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standardized education (Control)
Number of subjects: 66
Study: 36573005

Group type: EXPERIMENTAL
Intervention: COVID+ group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: COVID- group
Number of subjects: 1000
Study: 36573071

Group type: EXPERIMENTAL
Intervention: Smiling is Fun (internet-based treatment)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No treatment (control phase)
Number of subjects: 420
Study: 36573318

Group type: EXPERIMENTAL
Intervention: MASES enthesitis score
Number of subjects: 526
Study: 36573634

Group type: EXPERIMENTAL
Intervention: Omicron variant period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delta variant period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-Delta variant period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delta and Omicron (pre-BA.4/BA.5) variant periods
Number of subjects: 0
Study: 36573644

Group type: EXPERIMENTAL
Intervention: MAOA DNA methylation assessment via [11C]harmine PET
Number of subjects: 52
Study: 36573651

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (racemic ketamine hydrochloride) administered over a 40-minute intravenous infusion, 2 times per week on nonconsecutive days for 4 weeks (8 sessions)
Number of subjects: 30
Study: 36573717

Group type: EXPERIMENTAL
Intervention: Glimepiride treatment
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: High-dose glimepiride (2-4 mg/day)
Number of subjects: 509
Study: 36573804

Group type: EXPERIMENTAL
Intervention: Dietary intake of wholegrains, fiber, and resistant starch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary quality in children with CF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastrointestinal and respiratory microbiota analysis
Number of subjects: 0
Study: 36574052

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual oncology care (standard group, S)
Number of subjects: 98
Study: 36574199

Group type: EXPERIMENTAL
Intervention: iGlarLixi SoloStar pen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training by HCPs on iGlarLixi SoloStar pen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iGlarLixi SoloStar pen recommendation
Number of subjects: 0
Study: 36574248

Group type: EXPERIMENTAL
Intervention: High-climate impact label (red meat)
Number of subjects: 5049

Group type: EXPERIMENTAL
Intervention: Low-climate impact label (chicken, fish, vegetarian)
Number of subjects: 5049

Group type: COMPARATOR
Intervention: Control label (quick response code)
Number of subjects: 5049

Group type: EXPERIMENTAL
Intervention: Low-impact label
Number of subjects: 5049

Group type: EXPERIMENTAL
Intervention: High-impact label
Number of subjects: 5049

Group type: EXPERIMENTAL
Intervention: High-climate impact label
Number of subjects: 5049

Group type: EXPERIMENTAL
Intervention: Low-climate impact label
Number of subjects: 5049
Study: 36574256

Group type: EXPERIMENTAL
Intervention: 3-pronged COVID-19 vaccine messaging platform (4-minute video, 1-page flyer, scripted message from ED staff)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: 3-pronged COVID-19 vaccine messaging platform
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (no messaging platform)
Number of subjects: 496
Study: 36574387

Group type: EXPERIMENTAL
Intervention: LNG/EE TDS (delivering LNG 120 μg/day and EE 30 μg/day) for 12 weeks
Number of subjects: 36
Study: 36574408

Group type: EXPERIMENTAL
Intervention: Internet Attachment-Based Compassion Therapy (iABCT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 68
Study: 36574413

Group type: EXPERIMENTAL
Intervention: Home-based telemonitoring program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 36574434

Group type: EXPERIMENTAL
Intervention: Rapid glucose infusion (3 times 20 grams of glucose i.v. over 5 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous glucose infusion (60 grams of glucose continuously over 3 hours)
Number of subjects: 10
Study: 36574590

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 28
Study: 36574595

Group type: EXPERIMENTAL
Intervention: 0.75% ruxolitinib cream
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1072

Group type: COMPARATOR
Intervention: vehicle to 0.75% ruxolitinib cream
Number of subjects: 1072

Group type: COMPARATOR
Intervention: vehicle to 1.5% ruxolitinib cream
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: ruxolitinib cream (both strengths)
Number of subjects: 1072
Study: 36574616

Group type: EXPERIMENTAL
Intervention: Multicomponent training (MT) physical exercise intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 36574734

Group type: EXPERIMENTAL
Intervention: self-monitoring of diet, PA, and weight with tailored feedback messages (n = 251)
Number of subjects: 502

Group type: COMPARATOR
Intervention: self-monitoring alone (n = 251)
Number of subjects: 502
Study: 36574828

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ambezim-G (trypsin 5mg-chymotrypsin 5 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and trypsin-chymotrypsin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 36574867

Group type: EXPERIMENTAL
Intervention: BiVP with optimal AV delays derived from shortest VS1 and longest S1S2 in pigs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BiVP with optimal AV delays derived from shortest VS1 and longest S1S2 in patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BiVP with full-capture AV delay of >180 ms in patients
Number of subjects: 26
Study: 36574985

Group type: EXPERIMENTAL
Intervention: Community perceptions about COVID-19
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stigma associated with COVID-19
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Community attitudes towards COVID-19
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Impact of stigma on mental health
Number of subjects: 10
Study: 36575175

Group type: EXPERIMENTAL
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Inhalation technique observation
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Adherence assessment
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: In-person observation of inhalation technique
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Observation training for healthcare professionals
Number of subjects: 1400
Study: 36575298

Group type: EXPERIMENTAL
Intervention: Endotracheal tube biofilm (ETT-BF)
Number of subjects: 61
Study: 36575315

Group type: EXPERIMENTAL
Intervention: Wave 1 (first COVID wave)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Wave 2 (second COVID wave)
Number of subjects: 772
Study: 36575361

Group type: EXPERIMENTAL
Intervention: Nivolumab plus 8 Gy single fraction radiation therapy (RT)
Number of subjects: 28
Study: 36575390

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fluoroscopic-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Number of subjects: 96
Study: 36575394

Group type: EXPERIMENTAL
Intervention: Prior paracetamol intake
Number of subjects: 2646

Group type: COMPARATOR
Intervention: No prior paracetamol intake
Number of subjects: 2646
Study: 36575421

Group type: EXPERIMENTAL
Intervention: Omitting internal mammary node irradiation (IMNI)
Number of subjects: 214

Group type: COMPARATOR
Intervention: With internal mammary node irradiation (IMNI)
Number of subjects: 214
Study: 36575425

Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled carbon dioxide (CO)
Number of subjects: 0
Study: 36575444

Group type: EXPERIMENTAL
Intervention: CPC (Cetylpyridinium Chloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: O-cymen-5-ol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPC + O-cymen-5-ol
Number of subjects: 0
Study: 36575505

Group type: EXPERIMENTAL
Intervention: Pegloticase + oral methotrexate (15 mg/week) administered 4 weeks before and during pegloticase treatment (biweekly 8 mg infusion, ≤ 52 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study: 36575513

Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg once daily) plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and docetaxel (100 mg/m2)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab and docetaxel
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and docetaxel
Number of subjects: 355
Study: 36575531

Group type: EXPERIMENTAL
Intervention: Hearing aid (HA) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 36575536

Group type: EXPERIMENTAL
Intervention: Virtual Pediatric Trauma Center (VPTC) model of care using telemedicine
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard of care (consultation with a pediatric trauma center by telephone)
Number of subjects: 380
Study: 36575541

Group type: EXPERIMENTAL
Intervention: Diet based on Dietary Guidelines for Americans (DGA)
Number of subjects: 44
Study: 36575574

Group type: EXPERIMENTAL
Intervention: TCMR1
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: TCMR2
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Late TCMR biopsies
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Atrophy-fibrosis in TCMR biopsies
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: TCMR1 and TCMR2
Number of subjects: 175
Study: 36575626

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 535
Study: 36575812

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation for 17 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both groups (multidisciplinary rehabilitation and usual care)
Number of subjects: 27
Study: 36575817

Group type: EXPERIMENTAL
Intervention: EMAeHealth intervention plus usual care
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Usual care (traditional maternal education)
Number of subjects: 1080
Study: 36576026

Group type: EXPERIMENTAL
Intervention: Presence of MFTC MOAKS cartilage damage
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Presence of MFTC bone marrow lesions
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Medial meniscus extrusion or damage
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: MOAKS severity subscales for cartilage and meniscus damage
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Knees with presence of MRI-based pathologies
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: MRI-based grading of articular pathologies
Number of subjects: 599
Study: 36576091

Group type: EXPERIMENTAL
Intervention: STN1013001 (latanoprost cationic emulsion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost (other formulations)
Number of subjects: 0
Study: 36576173

Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib (avelumab 10 mg/kg every 2 weeks plus axitinib 5 mg twice daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 55
Study: 36576188

Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laptop-assisted guided imagery
Number of subjects: 80

Group type: COMPARATOR
Intervention: VR (no guided imagery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laptop (no guided imagery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VRAGI
Number of subjects: 80
Study: 36576191

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Adherence and Depression (PST-AD) - 6 sessions
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual care for viral non-suppression - 3 sessions of adherence counselling
Number of subjects: 290
Study: 36576323

Group type: EXPERIMENTAL
Intervention: AVATAR protocol (cryo-balloon ablation without electrical mapping, discharged same day)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Drug therapy (optimization of drug therapy)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Conventional ablation (cryo-balloon ablation with confirmation of pulmonary vein isolation and overnight hospitalization)
Number of subjects: 321
Study: 36576342

Group type: EXPERIMENTAL
Intervention: Scar core mass, border zone (BZ) mass, and presence of BZ channels in patients with VA
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Presence of BZ channels in patients with VA
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Combination of ≥17.2 g BZ mass and presence of BZ channels
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Scar characterization with CMR
Number of subjects: 843
Study: 36576365

Group type: EXPERIMENTAL
Intervention: Brief Primary Care-Based Mindfulness Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducational Group
Number of subjects: 0
Study: 36576430

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 172
Study: 36576431

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 32
Study: 36576547

Group type: EXPERIMENTAL
Intervention: Low-contrast-dose group (n = 43)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-contrast-dose group (n = 47)
Number of subjects: 90
Study: 36576860

Group type: EXPERIMENTAL
Intervention: Hormonal treatment for heavy menstrual bleeding
Number of subjects: 0
Study: 36576875

Group type: EXPERIMENTAL
Intervention: mHealth intervention (Aim2Be)
Number of subjects: 0
Study: 36576984

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 36577040

Group type: EXPERIMENTAL
Intervention: mRNA-3927 (an LNP encapsulating PCCA and PCCB mRNAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preclinical data from mice, rats, and monkeys
Number of subjects: 0
Study: 36577095

Group type: EXPERIMENTAL
Intervention: VV116
Number of subjects: 822

Group type: COMPARATOR
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 822
Study: 36577165

Group type: EXPERIMENTAL
Intervention: Sotorasib (first-in-class KRAS inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm treatment (inferior to the best standard of care)
Number of subjects: 0
Study: 36577235

Group type: EXPERIMENTAL
Intervention: Cognitive training plus aerobic exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cognitive training alone
Number of subjects: 39
Study: 36577492

Group type: EXPERIMENTAL
Intervention: Competitive activation, site navigators, supplemental funds for milestones
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Site navigators
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Competitive site activation
Number of subjects: 19
Study: 36577733

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) individuals
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 62
Study: 36577949

Group type: EXPERIMENTAL
Intervention: Mastery Lifestyle Intervention (MLI)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 221
Study: 36577968

Group type: EXPERIMENTAL
Intervention: Malakit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not participants in Malakit)
Number of subjects: 0